X Close

This hyperlink will direct you to a non-governmental Website or application.

The appearance of external hyperlinks does not constitute endorsement by the United States Department of Health & Human Services (HHS) of the hyperlinked Website or application, or the information, products or services contained therein. Such hyperlinks are provided consistent with the intended purpose of this HHS Website. Visitors to the hyperlinked Website or application will be subject to the Website or application's privacy policies. These practices may be different than those of this HHS Website.

You will be redirected to: link

• Home
• Quick Guide to Healthy Living
• Personal Health Tools
• Health A-Z
• Health News
• Find Services & Information
• Popular Requests
• Español

• E-cards
• National Health Observances

Office of Special Health Issues, U.S. Food and Drug Administration - OSHI/FDA

Organization URL(s)

OSHI@fda.hhs.gov
www.fda.gov/AboutFDA/CentersOffices/OC/OfficeofExternalAffairs/OfficeofSpecialHealthIssues/default.htm  

Other Contact Information

10903 New Hampshire Avenue
10903 New Hampshire Avenue
Bldg. 32, Room 5367


Silver Spring, MD 20993

888-463-6332 (Voice - Toll-free, 888-INFOFDA)
301-796-8460 (Voice)

Description

The Office of Special Health Issues (OSHI) is a liaison between the Food and Drug Administration (FDA) and patients, patient advocates, and health professional organizations. The staff encourages and supports active participation of these groups in forming FDA regulatory policy. OSHI responds to inquiries and concerns related to HIV/AIDS, cancer, and other special health issues. The staff is familiar with the concerns confronting patients and families dealing with a life-threatening illness. In addition, OSHI provides information about the FDA drug approval process and clinical trials, and administer MedWatch, the FDA Safety Information and Adverse Event Reporting Program.

Online Resources

• Patient Involvement in FDA Regulatory Issues
  http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/PatientInvolvement/default.htm
• What’s New at FDA in HIV/AIDS
  http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm122951.htm

Related Topics

Topic Cancer Clinical Trials HIV/AIDS Patient Advocacy Drug Safety Health Disparities

Review Date

Tue Aug 9, 2011